About Elagolix Sodium API
Therapeutic CategoryPain Management
CAS Number
832720-36-2
API Technology
High Potent
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF
Mechanism of Action
ORILISSA is a GnRH receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of ORILISSA results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones, estradiol and progesterone.
Indication
ORILISSA is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis.
Related APIs
Elagolix Sodium
Pain Management
Ketorolac Tromethamine
Pain Management
Naproxen
Pain Management
Naproxen Sodium
Pain Management
Naratriptan Hydrochloride
Pain Management
Sumatriptan Succinate
Pain Management
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related Resources
